血清胃蛋白酶原联合G-17 对萎缩性胃炎及胃癌早期诊断价值.

Objective: To research the diagnostic value of measuring serum pepsinogen I(PGI),pepsinogen II(PGII) and gastrin-17 (G-17) for atrophic gastritis and gastric cancer. Methods: A total of 44 patients were diagnosed with non-atrophic gastritis(non-atrophic gastritis group), 47 patients were chronic atrophic gastritis(atrophic gastritis group),42 were gastric cancer(gastric cancer group) were enrolled in the hospital February 2015 to December 2015.The serum PGI, PGII and G-17 levels were detected by enzyme-linked immunosorbent assay (ELISA), and PGI/II ratio (PGR) was calculated, compared above indexes in different groups, and drew the receiver operating curve (ROC) of above indexes, and analyzed their diagnostic value. Results: The levels of serumPGI and PGR in gastric cancer group and chronic atrophic gastritis group were significantly decreased than that of non-atrophic gastritis group, and gastric cancer group decreased more, the differences were statistically significant (P<0.05), the level of PGII in atrophic gastritis group was lower than non-atrophic gastritis group, the difference was statistically significant (P<0.05), the level of serum G-17 in gastric cancer were significantly increased than chronic atrophic gastritis and non-atrophic gastritis group, the differences were statistically significant (P<0.05). The optimal value of PGI screening for atrophic gastritis was PGI<90 ng/mL, its sensitivity and specificity were 71.5% and 51.0%, respectively. The optimal value of PGR screening for atrophic gastritis was PGR<8, its sensitivity and specificity were 71.9%and 54.0%, respectively. The optimal value of G-17 screening for atrophic gastritis was G-17<5 pmol/L, its sensitivity and specificity were 66.1%and 64.0%, respectively. The optimal value of PGI screening for gastric cancer was PGI<73 ng/mL, its sensitivity and specificity were 86.0% and 74.9%, respectively. The optimal value of PGR screening for gastric cancer was PGR<3, its sensitivity and specificity were 90.2% and 62.5%, respectively. The optimal value of G-17 screening for gastric cancer was G-17<4 pmol/L, its sensitivity and specificity were 62.5% and 61.3%, respectively. Conclusion: The levels of serum PGI and PGR in patients with gastric cancer and atrophic gastritis are significantly decreased, and the serum G-17 of the patients with gastric cancer are abnormally increased, detecting serum PG combined with G-17 can be used to screen early gastric cancer and chronic atrophic gastritis. [ABSTRACT FROM AUTHOR]